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A B S T R A C T
The potential for bacterial resistance probably existed
prior to the arrival of humans on earth and bacterial
populations isolated before the antibiotic era surely con-
tained antibiotic-resistant organisms. Antibiotic resistance
has undergone an explosive development following the
introduction of antibiotics in medical practice and in agricul-
I N T R O D U C T I O N
An increasing frequency and variety of antimicrobial
resistances is being documented in both the hospital and the
community.1 Recent emergence of multiple-drug resistance
in a variety of bacterial species such as Streptococcus
pneumoniae, Staphylococcus aureus,  Mycobacterium tzlbercu-
losis, or Enterococcus species poses a serious public health
challenge and raises the possibility of untreatable infections,
as they were encountered before the antimicrobial era.
Determining why resistance progresses is a difficult but
essential task for those involved in the fight against this
modern plague. Numerous factors associated with the
emergence of resistance have been identified, including
antibiotic use and abuse, microbial abilities to select and to
transmit resistance phenotypes and resistance genes, envi-
ronmental conditions promoting persistence or dissemina-
tion of resistance determinants, and presence of bacterial
reservoirs.1 This article focuses on the selection of antibiotic
resistance in patients receiving antibiotic therapy.
ture, and there is no doubt that the higher prevalence of
bacterial resistance is closely related to human activities.
Stri t infection control policies limit the risk of patient-to-
patient transmission of resistant as well as susceptible
bacteria (Infect Control Hosp Epidemiol 1994;15:472-477).
THE ANIW MODEL
A murine model was developed that allowed detection
nd quantification of the bacterial resistance that emerges
during or after antibiotic therapy.z-?-” Peritonitis was estab-
lished in mice by intraperitoneal bacterial challenge. Treat-
ment started 2 hours later and consisted of one to six
subcutaneous antibiotic doses. Therapeutic results were
evaluated in comparison with untreated control animals,
according to mortality, severity of the peritonitis, colony-
forming units (CFUs) in peritoneal fluid, and antibiotic
susceptibility patterns. Resistance emerged rapidly when it
occurred, often after the first antibiotic dose. Emergence of
resistance was not necessarily associated with therapeutic
failure. However, after a first antibiotic exposure in the
animal, gram-negative rods with post-therapeutic resistance
k pt the virulence of the parent strain, and were subject to
further selection of a higher level of resistance after a
subs quent antibiotic challenge in the same model.
In gram-negative bacteria, low-level post-therapeutic
resistances to p-lactam and quinolones (four- to eightfold
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increase in the minimum inhibitory concentration [MIC])
was caused by outer membrane impermeability, whereas
the highly resistant bacteria combined impermeability and
production of chromosomal B-l ctamase or altered DNA-
gyrase.4-6 The outer membrane defects often caused cross-
resistance to structurally unrelated antibiotics. For example,
quinolones regularly selected quinolone-resistant Pseudo-
monas aeruginosa with decreased susceptibility to imipenem
associated with decreased expression of OprD, the porin
channel that catalyzes facilitated diffusion of im penem.4,j
Emergence of resistance depended on several parameters.
Enterobacter cloacae  and P aeruginosa were the most prone
to manifest resistance, followed by Serratia marcescens and
Klebsiella pneumoniae, as opposed to Escherichia coli and S
aureus.
Aminoglycosides, imipenem, and cefepime were associ-
ated less with resistance than were third-generation c pha-
losporins and quinolones (Table 1). In particular, studies
have demonstrated the possibility of selecting methicillin-
resistant S aureus that also is quinolone-resistant during
quinolone treatment of experimental endoc rditis.7 Under-
dosing, either by lowering antibiotic doses or by enlarging
dosing intervals, promoted occurrence of resistance,2x4 as
did the higher inocula, or the presence of talcum used as a
foreign body in the peritoneal cavity.a By contrast, the
combination of B-lactam plus aminoglycoside or quinolone
plus aminoglycoside clearly reduced the risk of resistance
during therapy.g In other P aeruginosa models, aminoglyco-
side-ß-lactam combinations reduced the emergence of resis-
tant organisms in neutropenic rat peritonitislO but not in
rabbit aortic valve endocarditisll
DEVELOPMENT OF RESISTANCE
Monotherapy
Patients receiving antibiotic therapy often experience
the increase of resistant bacteria, as is well documented by
a number of prospective clinical studies.12 Resistance emerg-
ing during therapy occurs both among colonizing bacteria
and in the pathogens targeted by the treatment. In many
cases, the MIC increases are substantial, with organisms
passing from the “susceptible” to the “resistant” category
during antibiotic exposure. One possible problem for evalu-
ating the changes of susceptibility patterns in this context is
the actual identity of isolates over the course of time, even
when they belong to the same species. DNA probing has
confirmed that failures to eradicate P aeruginosa in clinical
infections can be due to development of resistance within a
given clone, as opposed to selection of new populations or
re-infection,13 but further studies are required to evaluate
the respective contribution of selection versus transmission
of resistance.
Careful analysis of prospective studies that included
large numbers of patients12 showed that the mean resistance
rates during monotherapy in strains that seemingly caused
infection (excluding colonizing bacteria) ranged from 4.7%
to 13.4% (Table 2). In accordance with the animal model, P
aeruginosa appeared particularly to be able to produce
resistance during therapy, followed by the Serratia species
and, in the case of therapy with broad spectrum penicillins,
TABLE 1
EMERGENCE OF  R ESISTANCE A FTER SHORT-TERM THERAPY
WITH DIFFERENT ANTIBIOTICS IN MICE CHALLENGED WITH
EN T E R O B A C T E R C W A C A E
Antibiotic
Ceftriaxone
Cefotaxime
Ceftazidime
Aztreonam
Carumonam
Imipenem
Cefepime
Piperacillin
SCH 34343
Pefloxacin
Ciprofloxacin
Amikacin
No. of % Yielding
Dose Treated Resistant
(mWW Mice Bacteria
50 23 87
50 36 76
50 24 58
50 24 42
25x2 24 21
50 24 <5
25x2 19 <5
200 12 ~8
25x2 20 s5
25 27 41
25 20 40
15 20 G5
Adapted from Michk+Hamzehpour, Lucain, and P&h&e.”
Proteus species. Other problematic organisms include Enter-
obacter species (notably during E terobacter bacteremia14),
strict anaerobes, Staphylococcus epidermidis, etc. In addition
to prospective studies, numerous anecdotal reports have
documented emergence of resistance in infections caused
by Salmonella species.15,16 Helicobacter pylori  in the context
of peptic ulcer,17 S pneumoniae,ls  and, needless to say, M
tuberculosis. Resistance can emerge with almost any site of
infection: skin wound, pneumonia, meningitis, bacteremia,
osteomyelitis, etc. Although, to my knowledge, no study has
addressed this question specifically, it has been suggested
that some host factors might promote emergence of resis-
tance, such as impaired host-defense mechanismslg or
cystic fibrosis.20
Emergence of resistance during therapy also depends
on the drug administered to the patient. According to an
extensive review dealing with a great number of patients,12
and in accordance with in vitro stepwise selection of resis-
tancezl, aminoglycosides appeared to be efficient selectors
when used alone or when the concomitantly given antibiotic
was not effective against the invading pathogen (Table 2).
The ability to produce resistance has been observed with all
minoglycoside drugs, particularly in urinary tract infec-
tion , where monotherapy with antibiotics is a common
practice.
Development of resistance to ciprofloxacin was detected
i  8 (36%) of 22 P aeruginosa isolates and in 3 (14%) of 22 S
aureus isolates from patients on ciprofloxacin therapy,
according to a recent prospective study.22 In accordance
with in vitro21 and experimental4 findings, ciprofloxacin
selected OprD deficient mutants, with reduced susceptibility
to imipenem. In addition, enoxacin therapy has been shown
to select cross-resistance affecting quinolones, some B-
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TABLE 2
DEVELOPMENT OF  R ESISTANCE D URING MONOTHERAPY
Percent of Patients with:
Studies Acquired Therapeutic
Antibiotics (Patients) Resistance Failure Most Frequent Pathogens
Broad-spectrum penicillins
2nd-3rd-generation
cephalosporin
Imipenem
Ciprofloxacin
Aminoglycosides
6 (170) 9.2 5.2 Pseudomonas aeruginosa, Boteus
species, Serratia species
9 (350) 8.6 4.3 Pseudomonas aeruginosa,
Sewatia  species
5 (277) 4.7 2.5 Pseudomonas aeruginosa
7 (322) 11.8 4.4 Pseudomonas aeruginosa,
Serratia species
5 (142) 13.4 11.4 Pseudomonas aeruginosa,
Serratia species
Adapted from Milatovic and Braveny.12
lactams, and chloramphenicol, with OmpF deficiency and
altered lipopolysaccharide as possible mechanisms.25 Develop
ment of quinolone resistance seems to be especially rapid in
methicillin-resistant S aureus.23-24  Quinolone resistance
emerges most frequently in hospitalized and nursing-home
patients,7 especially where large numbers of microorgan-
isms are present7 Emergence of P aeruginosa infections in
the course of ciprofloxacin therapy was associated fre-
quently with underdosing, anatomical abnormalities, or the
presence of foreign bodies.26
Resistance emerged in 3.6% to 35.7% of patients receiv-
ing third-generation cephalosporins, with an especially high
risk attached to cefsulodin in P aeruginosa infectionsZ7
These resistances may occur despite combination with
aminoglycosidesz7 and produced clinical failures in about
half the cases,t2 some with serious consequences in patients
with impaired host defenses.lg
Imipenem selected resistance in about 5% of patients,12
almost solely in P aeruginosa infections, where the carbap-
enem can select OprD-deficient mutants.
Combined Therapy
The actual contribution of antimicrobial combinations
in limiting occurrence of resistance still is not clarified
entirely, but it seems likely in some areas. From the very
earliest studies, it appeared that during the treatment of
tuberculosis, resistance to any single antibiotic developed
readily, and that combinations of antibiotics were necessary
to limit the emergence of r sistance.28 For the same pur-
pose, it is also common practice to use combined antibiotic
therapy for serious P aeruginosa infections. Two recent
prospective studies showed that, with a new B-l &m or
ciprofloxacin with concurrent use of an aminoglycoside, the
risk of emergence of resistance was reduced in hospital
practice,22,2g but other studies were unconclusive,30,31 and
more investigations aiming at comparing development of
resistance in monotherapy and combination therapy still are
necessary to get a definitive answer to this important issue.
POSSIBLE ROLE OF INTESTINAL FLORA
The studies quoted above demonstrate that selection of
resista ce is a common event among the bacteria causing
various types of infections, but the normal flora of a host
receiving antibiotics also deserve consideration. The bowel
represents, by far, the main human reservoir for bacteria.
The intestine contains several hundred obligate anaerobic
species,32 for a total of 10” to 1012 CFU/g of feces. The
concentration of the aerobic flora is one thousand times
lower, represented by a small number of species of gram-
negative bacilli (E coli is predominant) and gram-positive
cocci, notably enterococci. The skin, the oropharynx, and
the vagina can be considered as additional reservoirs of
lesser importance in terms of absolute numbers of bacteria
and bacterial concentrations they contain. Selection of
resistant bacteria can occur in any of these reservoirs during
antibiotic therapy, but the intestine is probably the dominant
niche of this selection due to the abundant and rich intestinal
flora where resistant genes can persist and circulate.
A concept called “colonization resistance” has been
developed, which posits that indigenous anaerobic flora
suppress the overgrowth of potentially pathogenic, mostly
aerobic flora.s3 The impact of antimicrobials on intestinal
microflora can be described according to four ca egories33:
very limited effect; selective decontamination of potential
pathogens preserving colonization resistance; inhibition of
colonization resistance with possible overgrowth of resistant
pathogens; and unselective decontamination. A number of
studies have demonstrated that administration of antibiotics
may result in the overgrowth of intestinal microorganisms
resistant to the administered drug.33l34
Table 3 indicates that overgrowth of resistant strains in
th  int stine lumen can accompany most antibiotic thera-
pies, with a few exceptions. Some drugs, like cephradine,
enjoy complete digestive absorption and rapid renal excre-
tion, providing probably very low levels in feces and conse-
quently, limited effects on fecal flora.36 Imipenem interferes
lit le with colonization resistance and produces no signifi-
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cant resistance selection.37 Oral administration of nitroimi-
dazoles causes no significant changes in the intestinal flora
despite their potent in vitro antibacterial effect against a
majority of intestinal obligate an erobes.34 Oral quinolones
cause major effects on enterobacteriaceae, but do not seem
to predispose to development of resistant bacteria,34 and
consequently can be used as selective decontaminating
agents. The fact that these antibiotic agents apparently are
unable to select bacterial resistance in the bowel suggests
the possibility that resistance to these agents is produced
elsewhere, perhaps in the infectious foci or in the environ-
ment. It is also worthwhile to mention that of 11 studies that
provide data about emergence of resistance during selective
decontamination, 10 reported no increase in resistant micro-
organisms.38
RELATION TO ANTIBIOTIC USE
If antibiotic resistance is selected in our patients,
extensive use of antibiotics in human medicine should fuel
the resistance crisis.3g A causal relationship between antibi-
otic usage and bacterial resistance is supported by concur-
rent variations in hospital ractice.40 Some observations also
may suggest that the same trait is observed in the commu-
nity. The extremely high incidence of antibiotic resistance in
5’ pneumoniae  in Hungary may have resulted from uncon-
trolled use and easy access to antibiotics in this country.41 It
also has been suggested that erythromycin resistance in
pneumococci may increase in countries where the drug is
used extensively.42 Recent European data provide evidence
that ciprofloxacin-resistant strains of various species are
more frequent in southern Europe, where the consumption
of fluoroquinolones per capita also is higher.43The correla-
tion between antibiotic use and bacterial resistance is not
straightforward, however, and many other parameters have
to be considered besides antibiotic policies, such as infec-
tion control practices, presence or absence of resistance
genes in a given niche, selectivity and transmissibility of
these resistance genes, and antibiotic dosages. Examples of
noncorrelation between antibiotic consumption and antibi-
otic resistance exist. The introduction of a number of
antibiotics in U.S. hospitals was not followed by substantial
changes in the incidence of resistant strains 3 to 5 years
later.44 In one hospital, high-level use of gentamicin was
associated with rapid increase in aminoglycoside resistance,
whereas high-level use of amikacin produced the opposite
results.45 Decreased incidence of antibiotic resistance among
S aureus  despite increased antibiotic usage has been reported
at least onceA
C O N C L U S I O N
The potential for bacterial resistance probably existed
prior to the arrival of humans on earth and bacterial
populations isolated before the antibiotic era surely con-
tained antibiotic-resistant organisms: penicillinase was first
described in 1940 by Abraham and Chain, when no penicillin
was available for treating patients. However, antibiotic resis-
tance has undergone an explosive development following
the introduction of antibiotics in medical practice and in
agriculture, and there is no doubt that the higher prevalence
TABLE 3
EFFECT OF ANTIBIOTICS  ON I NTESTINAL MICROFLORA
Overgrowth of Resistant Strains in the
Dowel During Therapy
Antibiotic Class Yes No
Penicillins
Cephalosporins
Other p-lactams
Macrolides
Tetracyclines
Imidazoles
Li osamines
Quinolones
Ampicillin, Phenoxymethy-
amoxicillin, penicillin,
clavulanate,* bacampicillin,
pivampicillin, temocillin,
talampicillin, ticarcillin/
pivmecillinam, clavulanate,
azlocillin
Cefuroxime, cefazolin, Cephradine
cefaclor,* cefoxitin,
cefotiam, cefjxime,
cefotaxime,
cefoperazone,
ceftriaxone,
cefmenoxime
Aztreonam* Imipenem
Erythromycin
Tetracycline,
doxycycline
Metronidazole,
tinidazole
Clindamycin
Ciprofloxacin,*
enoxacin,
norfloxacin,*
ofloxacin,*
pefloxacine,
lomefloxacin
* Some studies have shown a different impact.
Adapted from Nord and Edland.”
of bacterial resistance is closely related to human activities.
Resistance can be selected in the environment, notably
through farmingactivities,47 but an array of evidence indi-
cates the important role of antibiotic therapy in our patients.
How could we limit the selection of antibiotic resis-
tance? Despite the introduction of potent new drugs (third-
and now fourth-generation cephalosporins, carbapenems,
and quinolones), more bacterial resistance is observed
today than 20 years ago, both in the community and in the
hospital,4s and it is unlikely that discovery and development
of ven more potent antibiotics will solve the problem.
Development of antibiotic policies often is presented as
essential,“a but action in this field is not obvious. At the world
level, certain incorrect practices should be eliminated: the
availability of antibiotics without prescription, over-the-
counter sales, poorly regulated manufacturing leading to
underdosed antibiotic products, antibiotic misuses (such as
aid treatment of immunocompetent patients with common
https://doi.org/10.2307/30148497
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upper respiratory tract infections of viral origin), abusive
antibiotic promotions by unscrupulous drug companies, or
the “just-in-case” philosophy adopted by anxious physicians
willing to cover “everything.”
Education is a key word here, but the task is immense.
Beyond obvious measures, many questions concerning an
appropriate antibiotic policy remain unanswered. In many
institutions, some recent and expensive antibiotics are kept
for very restricted indications and require a formal approval
before use; is this “reserve” policy correct in terms of
selection of bacterial resistance? Apart from some situations
in which the evidence is clear, such as tuberculosis, what are
the infections requiring a combined therapy for limiting the
risk of emerging resistance? In addition to imipenem in
non-Pseudomonas infections, what antibiotics are less prone
to select resistance and should be preferred on this basis?
For example, oral cephalosporins increasingly are used
instead of penicillin for treating bacterial pharyngitis. What
is the actual influence of this trend on bacterial resistance?
Should we avoid standardized therapy in which the same
drug is used any time and everywhere for a given disease
(for example, penicillin for gonorrhea), and instead, intro-
duce the concept of cycling the use of antibiotics? If so, what
cycle rhythm? In many developing countries, the resistance
crisis is present, and only a few cheap and old antibiotics are
available. What newer antibiotics should be introduced?
There certainly is a need for molecular epidemiology to
delineate more precisely the respective contribution of the
selection of resistance in patients receiving antibiotics and
the diffusion of resistance from person to person, but
European prevalence studies in intensive care units (Euronis,
EPIC, and personal unpublished data) indicate that coun-
tries with the lower rates of nosocomial infections (ie,
northern Europe) also enjoy lower rates of methicillin
resistance. Although this association may have several
explanations, there is at least one point on which a majority
of authorities will agree: strict infection control policies
limit the risk of patient-to-patient transmission of resistant as
well as susceptible bacteria.
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